Mapping cancer mutations to improve treatment options
A pan-cancer atlas of driver mutations in >100,000 patients based on a hypothesis-driven combined computational and experimental approach
This study is looking at how certain genetic changes in cancer can help us find new ways to treat it, using information from over 100,000 patients to discover better drug targets and treatment options that are tailored to each person's unique genetics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10795923 on NIH RePORTER |
What this research studies
This research investigates the role of specific mutations in cancer that drive tumor development, focusing on both coding and noncoding regions of the genome. By analyzing data from over 100,000 patients, the study aims to identify new drug targets and clinical markers that could lead to more effective therapies. The approach combines computational methods with experimental validation to understand how these mutations interact and influence cancer progression. Patients may benefit from insights that could lead to personalized treatment strategies based on their unique genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with various types of cancer who have specific mutations that may be targeted for therapy.
Not a fit: Patients with cancers that do not involve driver mutations or those who are not eligible for targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies targeting specific cancer mutations, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown promise in identifying driver mutations in cancer, suggesting that this approach could yield significant advancements in cancer treatment.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Dietlein, Felix — Boston Children's Hospital
- Study coordinator: Dietlein, Felix
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.